Oral PTH 1-34 (teriparatide)

• 2 Clinical Studies Completed
• Ongoing Formulation Optimization
  n.b. injectable form approved 12/02

Clinical Stage Partnerships

Previous slide

Next slide

Back to first slide

View graphic version